Exploring the relationship of cognitive function with and without COVID-19 recovered schizophrenic patients

Exploring the relationship of cognitive function with and without COVID-19 recovered schizophrenic patients

BackgroundThe Coronavirus disease 2019 (COVID-19) is linked to the deterioration of cognitive function among individuals suffering from schizophrenia. The purpose of this study was to compare the cognitive performance of schizophrenic patients before and after COVID-19.MethodsA longitudinal cohort s...

Full description

Bibliographic Details
Main Authors:	Anam Mehmood, Ali Madi Almajwal, Abdullah Addas, Falak Zeb, Iftikhar Alam, Bismillah Sehar
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Series:	Frontiers in Public Health
Subjects:	COVID-19 cognitive performance schizophrenia BACS PANSS
Online Access:	https://www.frontiersin.org/articles/10.3389/fpubh.2023.1306132/full

Similar Items

Cross-cultural adaptation and validation of the lebanese arabic version of the BACS scale (the brief assessment of cognition in schizophrenia) among stable schizophrenic inpatients
by: C. El Haddad, et al.
Published: (2021-04-01)

Cross-cultural adaptation and validation of the Arabic version of the BACS scale (the brief assessment of cognition in schizophrenia) among chronic schizophrenic inpatients
by: Chadia Haddad, et al.
Published: (2021-05-01)

Relationship of Neuropeptide S with Clinical and Metabolic Parameters of Patients during Rehabilitation Therapy for Schizophrenia
by: Agnieszka Markiewicz-Gospodarek, et al.
Published: (2022-06-01)

Prevalence of depression in persons with schizophrenia – A cross-sectional study from a tertiary psychiatric hospital
by: Reshma Susan Mathew, et al.
Published: (2023-06-01)

Amygdala signal abnormality and cognitive impairment in drug-naïve schizophrenia
by: Huagui Guo, et al.
Published: (2023-04-01)

Consensus five factor PANSS for evaluation of clinical remission: effects on functioning and cognitive performances
by: Federica Pinna, et al.
Published: (2014-12-01)

The Prevalence of Depressive Symptoms in Schizophrenia: A Cross-sectional Study
by: Senthilkumaran Chidambaram, et al.
Published: (2023-12-01)

Suicidal tendencies in Schizophrenia patients
by: A. Pascariu, et al.
Published: (2022-06-01)

Standardized training in the rating of the six-item positive and negative syndrome scale (PANSS-6)
by: P. Kølbæk, et al.
Published: (2021-04-01)

Acetaminophen as Adjuvant to Risperidone in Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
by: Somaye Arabzadeh, et al.
Published: (2018-02-01)

Association between cerebral dopamine neurotrophic factor (CDNF) 2 polymorphisms and schizophrenia susceptibility and symptoms in the Han Chinese population
by: Yongfeng Yang, et al.
Published: (2018-01-01)

Comparison of Classical and Clozapine Treatment on Schizophrenia Using Positive and Negative Syndrome Scale of Schizophrenia (PANSS) and SPECT Imaging
Published: (2005-05-01)

Symptom remission and functional outcome in an Egyptian sample of patients with schizophrenia
by: Reem El Ghamry, et al.
Published: (2021-12-01)

Relation of IGF-I and IGFBP5 gene expression levels in Schizophrenia patients
by: Sevgi Karabulut Uzunçakmak, et al.
Published: (2020-05-01)

Abnormalities of the Amygdala in schizophrenia: a real world study
by: Guangen Zheng, et al.
Published: (2023-08-01)

Overlapping of clinical symptoms between schizophrenia and bipolar disorder
by: A. Tahirovic, et al.
Published: (2022-06-01)

Violence, neurocognitive function and clinical correlates in patients with schizophrenia
by: Yun Yi, et al.
Published: (2023-01-01)

Relationship between TNF-α levels and psychiatric symptoms in first-episode drug-naïve patients with schizophrenia before and after risperidone treatment and in chronic patients
by: Chen Lin, et al.
Published: (2021-11-01)

Direct correlation between the scores of PANSS/AIMS scales and some oxidative stress markers in treated schizophrenic patients
by: Dobrin Romeo, et al.
Published: (2014-01-01)

Shorter Chain Triglycerides Are Negatively Associated with Symptom Improvement in Schizophrenia
by: Anna Tkachev, et al.
Published: (2021-05-01)

A Potential Biomarker for Predicting Schizophrenia: Metallothionein-1
by: Seda Yılmaz, et al.
Published: (2023-02-01)

Clinical and cortical similarities identified between bipolar disorder I and schizophrenia: A multivariate approach
by: Kelly Rootes-Murdy, et al.
Published: (2022-11-01)

Symptomatic Profile of Cariprazine in the Context of ICD-11 Domains for Schizophrenia: Review of Clinically Oriented Studies
by: Alexey Viktorovich Pavlichenko, et al.
Published: (2022-01-01)

French version validation of the psychotic symptom rating scales (PSYRATS) for outpatients with persistent psychotic symptoms
by: Favrod Jerome, et al.
Published: (2012-09-01)

Dataset on negative symptoms factors in patients with schizophrenia
by: T.V. Lezheiko, et al.
Published: (2022-02-01)

Sensitivity and applicability of the Brazilian version of the Brief Assessment of Cognition in Schizophrenia (BACS)
by: João Vinícius Salgado, et al.

Subjective cognitive complaints in first episode psychosis: A focused follow-up on sex effect and alcohol usage
by: E. Stip, et al.
Published: (2022-12-01)

Population Pharmacodynamic Models of Risperidone on PANSS Total Scores and Prolactin Levels in Schizophrenia
by: Zhiwei Huang, et al.
Published: (2024-01-01)

Effect of Vitamin D Supplementation on Cardiometabolic Indices and the Severity of Symptoms in Male Patients With Chronic Schizophrenia
by: Parinaz Kalejahi, et al.
Published: (2023-07-01)

Decreased serum levels of glial markers and their relation with clinical parameters in patients with schizophrenia
by: İhsan Çetin, et al.
Published: (2023-09-01)

Evaluation of the Effect of Alkaloid Berberine on the Positive and Negative Symptoms of the Patients with Schizophrenia: A Double-Blind Randomized Placebo-Controlled Clinical Trial
by: Ebrahim Moghimi Sarani, et al.
Published: (2022-09-01)

C-Reactive Protein Correlates with Negative Symptoms in Patients with Schizophrenia
by: Ted Boozalis, et al.
Published: (2018-01-01)

A new sex-specific underlying mechanism for female schizophrenia: accelerated skewed X chromosome inactivation
by: Xinzhu Zhang, et al.
Published: (2020-07-01)

Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics
by: Yi-Lung Chen, et al.
Published: (2018-12-01)

Subjectively-assessed cognitive impairment and neurocognition associations in schizophrenia inpatients
by: Tatsuhiko Masuzawa, et al.
Published: (2022-03-01)

Impaired insight in schizophrenia: impact on patient-reported and physician-reported outcome measures in a randomized controlled trial
by: Paul H. Lysaker, et al.
Published: (2022-08-01)

Positive and negative syndrome scale in forensic patients with schizophrenia spectrum disorders: a systematic review and meta-analysis
by: Chiara Buizza, et al.
Published: (2022-09-01)

Suicide Attempts, Neurocognitive Dysfunctions and Clinical Correlates in Middle-Aged and Elderly Chinese Schizophrenia Patients
by: Yuanyuan Huang, et al.
Published: (2021-05-01)

Associations of Genetic Polymorphisms and Neuroimmune Markers With Some Parameters of Frontal Lobe Dysfunction in Schizophrenia
by: Anna Morozova, et al.
Published: (2021-05-01)

Diagnostic value and role of serum miR-15a-5p in patients with schizophrenia
by: Zhen Xu, et al.
Published: (2024-01-01)